Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077374 · ClinicalTrials.gov registry record · Phase 2
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
A Phase 2 study, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT02077374: Completed Phase 2 study, sponsored by Conatus Pharmaceuticals.
NCT02077374 is a Phase 2 study that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02077374, a Phase 2 study, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and with abnormal liver tests
Primary Outcome
Mean change in alanine aminotransferase (ALT) from Baseline to Day 28/ET between IDN-6556 vs Placebo
Interventions
- OTHER Placebo
- DRUG IDN-6556
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT02077374 record still lists
NCT02077374 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02077374 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02077374 about?
NCT02077374 is a clinical study titled "A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases". The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and with abnormal liver tests
What is the current status of trial NCT02077374?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2014-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02077374?
The interventions under investigation include: Placebo (OTHER), IDN-6556 (DRUG).
Who is sponsoring clinical trial NCT02077374?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02077374's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia